1/21
Vocabulary practice flashcards covering growth hormone replacement therapy, associated endocrine disorders, diagnostic approaches, drug delivery systems, stability profiles, and GnRH agonist management based on the 2025 NASP CSP Exam Prep Course Study Guide.
Hypopituitarism
A condition characterized by the deficiency of one or more hormones produced by the pituitary gland (such as growth hormone, TSH, LH, FSH, ADH, prolactin, or oxytocin), caused by tumors, trauma, infection, or inflammation.
Panhypopituitarism
A medical condition defined as the complete deficiency of all hormones secreted by the pituitary gland.
Dynamic Hormone Stimulation Testing
A diagnostic procedure utilized when growth hormone (GH) or adrenocorticotropic hormone (ACTH) deficiency is suspected, or when morning fasting basal hormone testing yields unclear or non-definitive results.
Noonan Syndrome
An autosomal dominant congenital genetic disorder presenting with distinctive facial features, short stature, heart defects, skeletal malformations, and bleeding problems; confirmed by molecular genetic testing of associated genes including PTPN11, SOS1, RAF1, RIT1, and KRAS.
Prader-Willi Syndrome (PWS)
A complex genetic disorder caused by the loss of function of several genes on chromosome 15 (via deletion of paternal segment, maternal uniparental disomy, or imprinting), presenting with hypotonia, global developmental delay, hyperphagia, obesity, and hypothalamic hypogonadism.
Turner Syndrome
A chromosomal condition in females caused by the complete or partial absence of the second sex chromosome (45,X), clinically presenting with short stature, ovarian hypofunction, heart defects (such as coarctation of the aorta), lymphedema, webbed neck, and broad, flat chest.
Idiopathic Short Stature (ISS)
A clinical description defined as height below 2 standard deviations (SD) of the mean for age without an underlying endocrine, metabolic, or systemic etiology; somatropin therapy is indicated only if height is at least 2.25SD below the mean and predicted adult height is below normal range.
Somatropin Mechanism of Action
Recombinant human growth hormone that promotes linear growth, enhances IGF-1-mediated actions in cartilage, bone, and muscle, stimulates protein synthesis, promotes lipolysis and lipid oxidation, antagonizes insulin action, and causes sodium, phosphate, and water retention.
Somatropin Daily Administration Timing
Daily somatotropin administration is most effective when given subcutaneously at night before bedtime to mimic endogenous physiological pulsatile release; injection sites must be rotated to prevent localized lipoatrophy.
Once-Weekly Growth Hormone Formulations
Long-acting recombinant human growth hormone alternatives to daily injections, which include Skytrofa (lonapegsomatropin-tcgd), Sogroya (somapacitan-beco), and Ngenla (somatrogon-ghla), with dosing titrated based on growth response and IGF-1 levels.
Humatrope (somatropin)
A growth hormone brand supplied as 6mg, 12mg, and 24mg cartridges (stable refrigerated for 28days after reconstitution with Humatrope Cartridge Kit) and a 5mg multidose vial (stable refrigerated for 14days); phased out by manufacturer Lilly by mid-2025.
Genotropin MiniQuick
A prefilled, premeasured, single-dose, preservative-free somatropin formulation (0.2 to 2mg in 0.2mg intervals) that can be stored unmixed at room temperature for up to 3months and must be administered immediately or refrigerated for up to 24hours after reconstitution.
Norditropin FlexPro
A prefilled, premixed, preloaded multidose somatropin pen available in strengths of 5mg/1.5mL, 10mg/1.5mL, 15mg/1.5mL, and 30mg/3mL; once opened, it is stable refrigerated for 28days or at room temperature for up to 21days, and is compatible with the PenMate needle-hiding device.
Nutropin AQ NuSpin
A prefilled, premixed, preloaded multidose somatropin pen formulation (5mg/2mL, 10mg/2mL, and 20mg/2mL) that required refrigeration and use within 28days; all formulations were discontinued in the United States on December 31, 2024.
Saizen Click.easy and Easypod
An electronic autoinjector system for somatropin where unmixed Click.easy cartridges are stored at room temperature, reconstituted using a disposable kit, loaded into the Easypod smart injector device to track adherence, and stored refrigerated for up to 21days.
Zomacton / Zoma-Jet 10
A somatropin product supplied in 5mg vials (refrigerated stability of 14days) and 10mg vials (refrigerated stability of 28days), which can be administered with conventional syringes or the needle-free Zoma-Jet 10 delivery device.
Slipped Capital Femoral Epiphysis (SCFE)
A recognized orthopedic complication and precaution associated with pediatric growth hormone therapy; warrants immediate evaluation in any child who develops a limp or complains of hip or knee pain.
Central Precocious Puberty (CPP)
Early onset of sexual maturation occurring at an age at least 2 standard deviations younger than the population mean (defined as before age 8 in girls and before age 9 in boys), which can cause early growth plate fusion and shortened adult stature.
Leuprolide Acetate Mechanism of Action
A potent gonadotropin-releasing hormone receptor (GnRHR) agonist that induces an initial surge in LH and FSH secretion, followed by chronic receptor down-regulation, suppression of gonadotropins, and subsequent suppression of gonadal sex steroid production.
Lupron Depot-Ped (1-Month Weight-Based Dosing)
Intramuscular depot leuprolide acetate administered monthly for CPP at 7.5mg for weight ≤25kg, 11.25mg for weight >25 to 37.5kg, and 15mg for weight >37.5kg.
Fensolvi (leuprolide acetate)
A subcutaneous GnRH agonist suspension formulation supplied in a two-syringe kit (Syringe A with ATRIGEL diluent and Syringe B with 45mg lyophilized powder) administered by a healthcare professional once every 6months for central precocious puberty.
Insulin-Like Growth Factor 1 (IGF-1) Monitoring
A laboratory parameter monitored at baseline, every 3 to 6months, and following dose adjustments to titrate growth hormone replacement therapy and confirm biological responsiveness.